8月6日 - ** 药物开发商Fractyl HealthGUTS.O股价盘前大跌27.8%至1.35美元
** GUTS周二晚些时候宣布， (link)，拟公开发行股票和预先融资的认股权证；规模未披露
** 募集资金将用于支持Revita和Rejuva管道项目及其他用途
** 根据招股说明书，截至3月31日，GUTS拥有4890万股流通股 (link)
** 拉登伯格-塔尔曼（Ladenburg Thalmann）是此次发行的唯一簿记管理人
** 覆盖该股的所有三家券商均给予 "买入 "或更高评级；中位数 PT 10 美元--数据由 LSEG 编制
** 截至上次收盘，GUTS股价年累计下跌9.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.